LONDON (Dec 8): British researchers on Wednesday started recruitment for a clinical trial to test antiviral Covid-19 treatments for use in people early on in the disease who are at higher risks of complications, starting with Merck’s molnupiravir.
Britain became the first country in the world to approve molnupiravir, which was jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics, in November.
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) recommended the antiviral pill for use in people with mild to moderate Covid-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease.
The government said in October it had secured 480,000 courses of the Merck drug, and after its approval, officials said that its rollout would originally be through a trial.
“It is early on in the illness, when people are still being cared for in the community, that treatments for COVID-19 could have their greatest benefit,” chief investigator on the trial Professor Chris Butler said.
“This new trial will test whether exciting, new antiviral treatments that are more specific to Covid-19 help people in the community recover faster and reduce the need for treatment in hospital.”
The University of Oxford, which is leading the trial, said the first treatment to be investigated would be molnupiravir, also known as Lagevrio, but that it would be able to rapidly evaluate several antiviral treatments over time.
Researchers said that while earlier trials had shown new antivirals to be safe and highly effective in treating COVID-19, the new trial would help generate data on how well they work in populations that have high vaccine coverage, and would inform the broader rollout of the drug.
The study will look to recruit 10,600 people to test whether molnupiravir reduces the need for people to be admitted to hospital.
- How Germany could have WON the Battle of Britain: Mathematical study proves the Luftwaffe would have defeated the RAF if they had started THREE WEEKS earlier and focused on bombing airfields rather than cities
- Historic Trump impeachment trial to begin in earnest
- Oskar Gröning trial: ‘Bookkeeper of Auschwitz’ admits moral guilt
- The doomsday vault: the seeds that could save a post-apocalyptic world
- Bitter exchanges and incriminating evidence rock Trump's impeachment trial
- Donald Trump’s Senate impeachment trial has officially begun
- VE Day: our memories of the second world war and the day it ended
- Will Wade's wiretap scandal a small part in sordid underworld of college hoops recruiting
- Dark secrets of real-life ‘Bunga Bunga’ sex parties which led to ‘orgy’ scandals and ‘murder’ mystery
- Deadly coronavirus 'could ALREADY be in Britain': Heathrow passengers from Wuhan are placed in isolation as death toll soars to 17 and China prepares to ban ANYONE from leaving city of 11m
- Brexit is not ‘done’. We have to start talking about it again
- Britain's TalkTalk sells fiber network to CityFibre for 200 million pounds
- Russian spies hacked Ukrainian gas firm at center of Trump impeachment trial
- Rugby League World Cup: Prince Harry explains mental health initiative ahead of World Cup draw
- U.S. House Democrats unveil team to prosecute Trump in Senate trial
- Trump trial: Ken Starr and no stripes
- House Democrats name seven-member team to prosecute Trump in Senate trial
- Reinier's move to Real Madrid proves La Liga's growing global prominence
- How to make the world happier – and why it should be our first priority
- Is this Britain's loneliest singleton? Man with Asperger's, 29, has spent 14 YEARS struggling to get a date - and worries being unemployed due to his condition puts women off
Britain starts recruiting for real-world Covid antiviral trial have 575 words, post on www.theedgemarkets.com at December 9, 2021. This is cached page on Business News. If you want remove this page, please contact us.